Table 1.
Demographics and Characteristics of Patients in the Two Study Arms
| Characteristic | No adenovirus (n = 62) | Positive adenovirus (n = 18) | p-value |
|---|---|---|---|
| Mean age ± SD (years) | 48.8 ± 12.1 | 52.3 ± 13.0 | 0.8 |
| Gender (male/female) | 41 M/21 F | 12 M/6 F | 1.0 |
| Underlying disease | 0.6 | ||
| Cystic fibrosis | 14 (22.6%) | 4 (22.6%) | |
| Emphysema/COPD | 19 (30.6%) | 9 (50.0%) | |
| Idiopathic pulmonary fibrosis | 17 (27.4%) | 4 (22.2%) | |
| Other | 12 (19.4%) | 1 (5.6%) | |
| Immunosuppression | |||
| Cyclosporine/prednisone/azathioprine | 29 (46.8%) | 7 (38.9%) | 0.4 |
| Cyclosporine/prednisone/mycophenolate mofetil | 20 (32.3%) | 8 (44.4%) | |
| Other | 13 (21.0%) | 3 (16.7%) | |
| Any anti-lymphocyte globulin | 19 (30.6%) | 8 (44.4%) | 0.4 |
| Treatment for acute rejection | 34 (54.8%) | 3 (16.7%) | 0.01 |
| CMV viremia | 27 (43.5%) | 8 (44.4%) | 1.0 |
| Symptomatic CMV disease | 11 (17.7%) | 4 (22.2%) | 0.4 |